281 related articles for article (PubMed ID: 34286886)
41. Factor structure, internal reliability and construct validity of the Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT-SMS).
Smith LR; Mittal ML; Wagner K; Copenhaver MM; Cunningham CO; Earnshaw VA
Addiction; 2020 Feb; 115(2):354-367. PubMed ID: 31478272
[TBL] [Abstract][Full Text] [Related]
42. Adapting methadone inductions to the fentanyl era.
Buresh M; Nahvi S; Steiger S; Weinstein ZM
J Subst Abuse Treat; 2022 Oct; 141():108832. PubMed ID: 35870437
[TBL] [Abstract][Full Text] [Related]
43. Office-Based Methadone Treatment for Opioid Use Disorder and Pharmacy Dispensing: A Scoping Review.
McCarty D; Bougatsos C; Chan B; Hoffman KA; Priest KC; Grusing S; Chou R
Am J Psychiatry; 2021 Sep; 178(9):804-817. PubMed ID: 34315284
[TBL] [Abstract][Full Text] [Related]
44. Perceived Barriers and Facilitators to Providing Methadone Maintenance Treatment Among Rural Community Pharmacists in Southwestern Ontario.
Fonseca J; Chang A; Chang F
J Rural Health; 2018 Dec; 34(1):23-30. PubMed ID: 28872697
[TBL] [Abstract][Full Text] [Related]
45. Dynamic changes in methadone utilisation for opioid use disorder treatment: a retrospective observational study during the COVID-19 pandemic.
Kennalley AL; Fanelli JL; Furst JA; Mynarski NJ; Jarvis MA; Nichols SD; McCall KL; Piper BJ
BMJ Open; 2023 Nov; 13(11):e074845. PubMed ID: 37973543
[TBL] [Abstract][Full Text] [Related]
46. Usefulness of the Brief Pain Inventory in Patients with Opioid Addiction Receiving Methadone Maintenance Treatment.
Dennis BB; Roshanov PS; Bawor M; Paul J; Varenbut M; Daiter J; Plater C; Pare G; Marsh DC; Worster A; Desai D; Thabane L; Samaan Z
Pain Physician; 2016 Jan; 19(1):E181-95. PubMed ID: 26752486
[TBL] [Abstract][Full Text] [Related]
47. Opioid treatment program culture and philosophy: Views of OTP staff and state officials on implementing interim methadone treatment.
Burruss-Cousins K; Mitchell SG; Gryczynski J; Whitter M; Fuller D; Ibrahim A; Schwartz RP
J Subst Use Addict Treat; 2024 Feb; 157():209265. PubMed ID: 38103832
[TBL] [Abstract][Full Text] [Related]
48. Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders.
Carney T; Van Hout MC; Norman I; Dada S; Siegfried N; Parry CD
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012254. PubMed ID: 32068247
[TBL] [Abstract][Full Text] [Related]
49. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
Sadek J; Saunders J
BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
[TBL] [Abstract][Full Text] [Related]
50. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
51. Medication Adherence in Patients Undergoing Methadone Maintenance Treatment in Xi'an, China.
Zhou K; Li H; Wei X; Li X; Zhuang G
J Addict Med; 2017; 11(1):28-33. PubMed ID: 27649264
[TBL] [Abstract][Full Text] [Related]
52. Methadone medical maintenance in primary care. An implementation evaluation.
Merrill JO; Jackson TR; Schulman BA; Saxon AJ; Awan A; Kapitan S; Carney M; Brumback LC; Donovan D
J Gen Intern Med; 2005 Apr; 20(4):344-9. PubMed ID: 15857492
[TBL] [Abstract][Full Text] [Related]
53. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
54. A pilot study assessing acceptability and feasibility of hatha yoga for chronic pain in people receiving opioid agonist therapy for opioid use disorder.
Uebelacker LA; Van Noppen D; Tremont G; Bailey G; Abrantes A; Stein M
J Subst Abuse Treat; 2019 Oct; 105():19-27. PubMed ID: 31443887
[TBL] [Abstract][Full Text] [Related]
55. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study.
Morford KL; Tetrault JM; Zhou B; Li F; Gleeson B; Edelman EJ; Stein MD; Barry DT; Madden L
Drug Alcohol Depend; 2022 Dec; 241():109707. PubMed ID: 36423462
[TBL] [Abstract][Full Text] [Related]
56. Treatment retention, drug use and social functioning outcomes in those receiving 3 months versus 1 month of supervised opioid maintenance treatment. Results from the Super C randomized controlled trial.
Holland R; Maskrey V; Swift L; Notley C; Robinson A; Nagar J; Gale T; Kouimtsidis C
Addiction; 2014 Apr; 109(4):596-607. PubMed ID: 24304349
[TBL] [Abstract][Full Text] [Related]
57. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
[TBL] [Abstract][Full Text] [Related]
58. A trial of implementation facilitation to increase timely admission to methadone treatment.
Gryczynski J; Mitchell SG; Whitter M; Fuller D; Mitchell MM; Edelman EJ; Schwartz RP
J Subst Use Addict Treat; 2024 Jul; 162():209375. PubMed ID: 38642889
[TBL] [Abstract][Full Text] [Related]
59. Care Integration for Hepatitis C Virus Treatment Through Facilitated Telemedicine Within Opioid Treatment Programs: Qualitative Study.
Dickerson SS; George SJ; Ventuneac A; Dharia A; Talal AH
J Med Internet Res; 2024 Jun; 26():e53049. PubMed ID: 38865703
[TBL] [Abstract][Full Text] [Related]
60. OUD MEETS: A novel program to increase initiation of medications for opioid use disorder and improve outcomes for hospitalized patients being discharged to skilled nursing facilities.
Tassey TE; Ott GE; Alvanzo AAH; Peirce JM; Antoine D; Buresh ME
J Subst Abuse Treat; 2022 Dec; 143():108895. PubMed ID: 36215913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
